JP2008514626A - 哺乳動物治療剤としての植物pr−5タンパク質 - Google Patents
哺乳動物治療剤としての植物pr−5タンパク質 Download PDFInfo
- Publication number
- JP2008514626A JP2008514626A JP2007533697A JP2007533697A JP2008514626A JP 2008514626 A JP2008514626 A JP 2008514626A JP 2007533697 A JP2007533697 A JP 2007533697A JP 2007533697 A JP2007533697 A JP 2007533697A JP 2008514626 A JP2008514626 A JP 2008514626A
- Authority
- JP
- Japan
- Prior art keywords
- osmotin
- protein
- adiponectin
- use according
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
【選択図】なし
Description
[0001]本願は、2004年9月27日出願の米国仮特許出願番号60/613,647及び2005年2月28日出願の米国仮特許出願番号60/657,335に関する。
[0063]以下の文献は、本発明を可能にする程度まで、参照により組み込まれる:
Anzlovar, S.,Serra, M.D., Dermastia, M., and Menestrina, G. (1998). Membrane permeabilizingactivity of pathogenesis-related protein linusitin from flax seed. Mol. Plant-MicrobeInteract. 11, 610-617.
Becker, D.M.,and Guarente, L. (1991). High-efficiency transformation of yeast byelectroporation. In Methods Enzymol., C. Guthrie and G.R. Fink, eds. (New York: Academic Press) 194, 182-187.
Brakenhielm,E., Vietonmaki, N., Cao, R., Kihara, S., Matsuzawa, Y., Zhivotovsky, B.,Funahashi, T. and Cao, Y. (2004).Adiponectin-induced antiangiogenesis andantitumor activity involve caspase-mediated endothelial cell apoptosis. Proc.Natl. Acad. Sci. USA. 101, 2476-2481.
Breiteneder,H., and Ebner, C. (2000). Molecular and biochemical classification ofplant-derived food allergens. J. Allergy Clin. Immunol. 106, 27-36.
David, N.E.,Gee, M., Andersen, B., Naider, F., Thorner, J., and Stevens, R.C. (1997).Expression and purification of the Saccharomyces cerevisiae alpha-factor receptor(Ste2p), a 7-transmembrane-segment G protein-coupled receptor. J. Biol. Chem.272, 15553-15561.
Diez, J. J.,and Iglesias, P. (2003). The role of the novel adipocyte-derived hormoneadiponectin in human disease. Eur. J. Endocrinol. 148, 293-300.
Ding, S.T.,Liu, B. H. and Ko, Y.H. (2004). Cloning and expression of porcine adiponectinand adiponectin receptor 1 and 2 genes in pigs, J. Anim. Sci. 82 (11),3162-3174.
Eck, M.E. and Sprang,S. R. (1989). The structure of tumor necrosis factor-a at 2.6 A resolution. J.Biol. Chem. 264, 17595-17605.
Elble, R.(1992). A simple and efficient procedure for transformation of yeasts.Biotechniques 13,18-20.
Forsberg, H.,and Ljungdahl, P. O. (2001). Sensors of extracellular nutrients inSaccharomyces cerevisiae. Curr. Genet. 40, 91-109.
Fruebis, J.,Tsao, T.S., Javorschi, S., Ebbets-Reed, D., Erickson, M.R., Yen, F.T., Bihain,B.E. and Lodish, H.F. (2001). Proteolytic cleavage product of 30-kDa adipocytecomplement-related protein increases fatty acid oxidation in muscle and causesweight lodd in mice. Proc. Natl. Acad. Sci. USA. 98, 2005-2010.
Gimeno, CJ.,Ljungdahl, P.O., Styles, C.A.,and Fink, G.R. (1992) Unipolar cell divisions in the yeast Saccharomycescerevisiae lead to filamentous growth: regulation by starvation and RAS. Cell68, 1077-1090.
Hampsey, M.(1997). A review of phenotypes in Saccharomyces cerevisiae. Yeast 13,1099-1133.
Hancock, R.E,and Scott, M. G. (2000). The role of antimicrobial peptides in animal defenses.Proc. Natl. Acad. Sci. USA. 97:8856-8861.
Harashima, T.,and Heitman, J. (2002). The Galpha protein Gpa2 controls yeast differentiationby interacting with kelch repeat proteins that mimic Gbeta subunits. MoI. Cell.10, 163-173.
Herskowitz, L,and Jensen, R.E. (1991). Putting the HO gene to work: Practical uses formating-type switching. In Methods Enzymol., C. Guthrie and G.R. Fink, eds. (New York : Academic Press) 194, 132-145.
Ibeas, J.I.,Lee, H., Damsz, B., Prasad, D.T., Pardo, J.M., Hasegawa, P.M., Bressan, R.A.,and Narasimhan, M.L. (2000). Fungal cell wall phosphomannans facilitate thetoxic activity of a plant PR-5 protein. Plant J. 23, 375-383.
Ibeas, J.I.,Yun, D. -J., Damsz, B., Narasimhan, M.L., Uesono, Y., Ribas, J.C., Lee, H.,Hasegawa, P.M., Bressan, R.A., and Pardo, J.M. (2001). Resistance to the plantPR- 5 protein osmotin in the model fungus Saccharomyces cerevisiae is mediatedby the regulatory effects of SSDl on cell wall composition. Plant J. 25,271-280.
Jazwinski, S.M. (1999). The RAS genes: a homeostatic device in Saccharomyces cerevisiaelongevity. Neurobiol. Aging 20, 471-478.
Jones, E. Y.,Stuart, D. I., and Walker, N.P. (1989). Structure oftumour necrosis factor. Nature. 338, 225-228.
Kaneko, R.,and Kitabatake, N. (2001). Structure-sweetness relationship in thaumatin:importance of lysine residues. Chem Senses 26, 167-177.
Karpichev, I. V., Cornivelli, L. and Small, G. M.(2002). Multiple regulatory roles of a novel Saccharomyces cerevisiae protein,encoded by YOL002c, in lipid and phosphate metabolism. J. Biol. Chem. 277,19609-19617.
Karpusas, M.,Hsu, Y. M., Wang, J.H., Thompson, J., Lederman, S., Chess, L., and Thomas, D.(1995). A crystal structure of an extracellular fragment of human CD40 ligand.Structure. 3, 1031-1039.
Kubota, JN.,Terauchi, Y., Yamauchi, T., Kubota, T., Moroi, M., Matsui, J., Eto, K.,Yamashita, T., Kamon, J., Satoh, H., Yano, W., Froguel, P., Nagai, R., Kimura,S., Kadowaki, T., and Noda, T. (2002). Disruption of adiponectin causes insulinresistance and neointimal formation. J. Biol. Chem. 277, 25863-25866.
Li, X.,Staszewski, L., Xu, H., Durick, K., Zoller, M. & Adler, E. (2002). Humanreceptors for sweet and umami taste. Proc: Natl. Acad. Sci. USA 99, 4692-4696.
Liu, H.,Krizek, J. & Bretscher, A. (1992). Construction of a GALL-regulated yeastcDNA expression library and its application to the identification of geneswhose overexpression causes lethality in yeast. Genetics 132, 665-673.
Lyons, T.J., Villa, N. Y., Regalia, L.M., Kupchak, B.R., Vagstad, A., andEide, DJ. (2204). Metalloregulation of yeast membrane steroid receptorhomologs. Proc. Natl. Acad. Sci. USA 101, 5506-5511.
Min, K., Ha,S.C., Hasegawa, P.M., Bressan, R.A., Yun, DJ. and Kim, K.K. (2004). Crystal structure of osmotin, a plantantifungal protein. Proteins 54, 170-174.
Monk, B.C.,Montesinos, C, Ferguson, C,Leonard, K., and Serrano, R. (1991). Immunological approaches to thetransmembrane topology and conformational changes of the carboxyl-terminalregulatory domain of yeast plasma membrane H(+)- ATPase. J. Biol. Chem. 266,18097-18103.
Mumberg, D.,Muller, R., and Funk, M. (1995). Yeast vectors for the controlled expression ofheterologous proteins in different genetic backgrounds. Gene 156, 119-122.
Narasimhan,M.L., Damsz, B., Coca, M.A., Ibeas, J.I., Yun, D. -J., Pardo, J.M., Hasegawa,P.M., and Bressan, R.A. (2001). A plant defense protein induces microbialapoptosis. MoI. Cell 8, 921-930.
Narasimhan, M.L., Lee, H., Damsz, B., Singh, N. K., Ibeas, J. L., Matsumoto, T.K., Woloshuk,C. P. and Bressan, R. A. (2003). Overexpression of a cell wall glycoprotein inFusarium oxysporum increases virulence and resistance to a plant PR- 5 protein.Plant J. 36: 390-400.
Nicholls, A.,Sharp, K. A. and Honig, B. (1991) Protein folding and association: insightsfrom the interfacial and thermodynamic properties of hydrocarbons. Proteins 11: 281-296.
Robzyk, K.,and Kassir, Y. (1992). A simple and highly efficient procedure for rescuingautonomous plasmids from yeast. Nucleic Acids Res. 20, 3790.
Rolland, F.,Winderickx, J. and Thevelein, J.M. (2002). Glucose-sensing and - signalingmechanisms in yeast. FEMS Yeast Res. 2, 183-201.
Scherer, P.E.,Williams, S., Fogliano, M., Baldini, G., and Lodish, H.F. (1995). A novel serumprotein similar to C 1 q, produced exclusively in adipocytes. J. Biol. Chem.270, 26746-26749.
Shapiro L,Scherer PE. (1998). The crystal structure of a complement-lq family proteinsuggests an evolutionary link to tumor necrosis factor. Curr. Biol. 8:335-338.
Sherman, F. (1991).Getting started with yeast. In Methods in Enzymology, eds. Guthrie, C. &Fink, G.. R. (Academic Press, New York), 194, 3-21.
Stanhill, A.,Schick, N., and Egelberg, D. (1999). The yeast Ras/cyclic AMP pathway inducesinvasive growth by suppressing the cellular stress response. MoI. Cell. Biol. 19,7529-7538.
Veronese, P.,Ruiz M. ., Coca, M. A., Hernandez-Lopez, A., Lee, H., Ibeas, J. I., Damsz, B.,Pardo, J. M., Hasegawa, P. M., Bressan, R. A., & Narasimhan, M. L. (2003)In defense against pathogens. Both plant sentinels and foot soldiers need toknow the enemy. Plant Physiol. 131, 1580-1590.
Wach, A.,Brachat, A., Alberti-Segui, C, Rebischung, C, and Philippsen, P. (1997).Heterologous HIS3 marker and GFP reporter modules for PCR-targeting in Saccharomycescerevisiae. Yeast, 13, 1065-1075.
Weickmann,J.L., Blair, L. C, and Wilcox, G.L. (1994) High level expression of thaumatinin Saccharomyces cerevisiae. In Thaumatin, M. Witty and J.D. Higginbotham, eds.(Boca Raton: CRC Press) pp. 151- 169.
Weis, W.I.,and Drickamer, K. (1994). Trimeric structure of a C-type mannose- bindingprotein. Structure. 2, 1227-1240.
Yamauchi, T.,Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., Mori, Y., Ide, T.,Murakami, K., Tsuboyama-Kasaoka, N., Ezaki, O., Akanuma, Y., Gavrilova, O.,Vinson, C, Reitman, M.L., Kagechika, H., Shudo, K., Yoda, M., Nakano, Y., Tobe,K., Nagai, R., Kimura, S., Tomita, M., Froguel, P., and Kadowaki, T. (2001 a).The fat-derived hormone adiponectin reverses insulin resistance associated withboth lipoatrophy and obesity. Nat. Med. 7, 941-946.
Yamauchi, T.,Waki, H., Kamon, J., Murakami, K., Motojima, K., Komeda, K., Miki, H., Kubota,N., Terauchi, Y., Tsuchida, A., Tsuboyama-Kasaoka, N., Yamauchi, N., Ide, T.,Hori, W., Kato, S., Fukayama, M., Akanuma, Y., Ezaki, O., Itai, A., Nagai, R.,Kimura, S., Tobe, K., Kagechika, H., Shudo, K., and Kadowaki, T. (2001b).Inhibition of RXR and PPARgamma ameliorates diet-induced obesity and type 2diabetes. J. Clin. Invest. 108, 1001-1013.
Yamauchi, T.,Kamon, J., Ito, Y., Tsuchida, A., Yokomizo, T., Kita, S., Sugiyama, T.,Miyagishi, M., Hara, K., Tsunoda, M., Murakami, K., Ohteki, T., Uchida, S.,Takekawa, S., Waki, H., Tsuno, N.H., Shibata, Y., Terauchi, Y., Froguel, P.,Tobe, K., Koyasu, S., Taira, K., Kitamura, T., Shimizu, T., Nagai, R., andKadowaki, T. (2003a). Cloning of adiponectin receptors that mediateantidiabetic metabolic effects. Nature. 423, 762-769.
Yamauchi,T.,Kamon, J., Waki, H., Imai, Y., Shimozawa, N., Hioki, K., Uchida, S.,Ito, Y.,Takakuwa, K., Matsui, J., Takata, M., Eto, K., Terauchi, Y., Komeda, K., Tsunoda,M., Murakami, K., Ohnishi, Y., Naitoh, T., Yamamura, K., Ueyama, Y., Froguel,P., Kimura, S., Nagai, R., and Kadowaki, T. (2003b). Globular adiponectinprotected ob/ob mice from diabetes and ApoE-deficient mice fromatherosclerosis. J. Biol. Chem. 278, 2461-2468.
Yun, D-J.,Ibeas, J.I., Lee, H., Coca, M.A., Narasimhan, MX., Uesono, Y., Hasegawa, P.M.,Pardo, J.M., and Bressan, R.A. (1998). Osmotin, a plant antifungal protein,subverts signal transduction to enhance fungal cell susceptibility. MoI. Cell1, 807- 817.
Yun, D-J.,Zhao, Y., Pardo, J.M., Narasimhan, M.L., Damsz, B., Lee, H., Abad, L.R.,D'Urzo, M.P., Hasegawa, P.M., and Bressan, R.A. (1997). Stress proteins on theyeast cell surface determine resistance to osmotin, a plant antifungal protein.Proc. Natl. Acad. Sci. USA. 94, 7082-7087.
Zhou, Z.Gartner, A., Cade, R., Ammerer, G. and Errede, B. (1993). Pheromone- inducedsignal transduction in Saccharomyces cerevisiae requires the sequentialfunction of three protein kinases. Mol.Cell. Biol. 13, 2069-2080.
Claims (30)
- レクチン様βバレルドメインを有するPR−5タンパク質を含む、医薬組成物。
- 前記PR−5タンパク質は、オスモチン[配列番号3]又はレクチン様βバレルドメインを有するそのホモログである、請求項1記載の医薬組成物。
- アディポネクチン又はアディポネクチン様タンパク質によって媒介される代謝経路の活性化又は阻害の結果である障害、に罹患した哺乳動物を治療するための方法であって、レクチン様βバレルドメインを有するPR−5タンパク質の投与を含む、方法。
- 前記障害は、II型糖尿病、インスリン抵抗性、高脂血症、動脈硬化及び心疾患からなる群より選択される、請求項3に記載の方法。
- 前記障害は、II型糖尿病である、請求項4に記載の方法。
- 前記障害は、インスリン抵抗性である、請求項4に記載の方法。
- 前記障害は、高脂血症である、請求項4に記載の方法。
- 前記障害は、動脈硬化である、請求項4に記載の方法。
- 前記障害は、心疾患である、請求項4に記載の方法。
- 前記PR−5タンパク質は、オスモチン[配列番号3]又はレクチン様βバレルドメインを有するオスモチンのホモログである、請求項3に記載の方法。
- 前記PR−5タンパク質は、オスモチン[配列番号3]又はレクチン様βバレルドメインを有するオスモチンのホモログである、請求項4に記載の方法。
- 哺乳動物細胞における、アディポネクチンの標的の全て又は一部のアゴニスト又はアンタゴニストである治療剤の合理的設計における、PR−5タンパク質の使用。
- 前記治療剤がアゴニストである、請求項12に記載の使用。
- 前記治療剤がアンタゴニストである、請求項12に記載の使用。
- 前記PR−5タンパク質がオスモチン[配列番号3]である、請求項12に記載の使用。
- 前記合理的設計が構造/機能分析を含む、請求項12に記載の使用。
- 哺乳動物細胞における、アディポネクチンの標的の全て又は一部のアゴニスト又はアンタゴニストである治療剤の合理的設計における、レクチン様βバレルドメインを有するPR−5タンパク質をコードする核酸配列の使用。
- 前記治療剤は、アゴニストである、請求項17に記載の使用。
- 前記治療剤は、アンタゴニストである、請求項17に記載の使用。
- 前記核酸配列は、配列番号1である、請求項17に記載の使用。
- 前記核酸配列は、配列番号2である、請求項17に記載の使用。
- 前記合理的設計は、構造/機能分析を含む、請求項17に記載の使用。
- 前記構造/機能分析は、DNAシャッフリング、増強された選択的変異誘発及びファージディスプレイからなる群より選択される1種又は複数の技術を含む、請求項22に記載の使用。
- 哺乳動物細胞における、アディポネクチンの標的の全て又は一部のアゴニスト又はアンタゴニストである治療剤を同定するための一次スクリーニングとしての、レクチン様βバレルドメインを有するPR−5タンパク質に対する特異的結合親和性を有するレセプタータンパク質の使用。
- 前記PR−5レセプターは、PHO36である、請求項24に記載の使用。
- 前記スクリーニングは、単離された形態のレセプターを使用して実施される、請求項24に記載の使用。
- 前記スクリーニングは、前記レセプターを発現する細胞株又は組織培養物を使用して実施される、請求項24に記載の使用。
- 細胞株又は組織培養物が前記レセプターを過剰発現している、請求項27に記載の使用。
- 前記スクリーニングは、酵母細胞株を使用して実施される、請求項27に記載の使用。
- 酵母が前記レセプターを過剰発現している、請求項29に記載の使用。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61364704P | 2004-09-27 | 2004-09-27 | |
US65733505P | 2005-02-28 | 2005-02-28 | |
US11/234,115 US20060069024A1 (en) | 2004-09-27 | 2005-09-26 | Plant PR-5 proteins as mammalian therapeutic agents |
PCT/US2005/034368 WO2006036871A2 (en) | 2004-09-27 | 2005-09-27 | Plant pr-5 proteins as mammalian therapeutic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2008514626A true JP2008514626A (ja) | 2008-05-08 |
Family
ID=36100046
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007533697A Pending JP2008514626A (ja) | 2004-09-27 | 2005-09-27 | 哺乳動物治療剤としての植物pr−5タンパク質 |
Country Status (4)
Country | Link |
---|---|
US (3) | US20060069024A1 (ja) |
EP (1) | EP1802323A2 (ja) |
JP (1) | JP2008514626A (ja) |
WO (1) | WO2006036871A2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011115106A1 (ja) * | 2010-03-16 | 2011-09-22 | 国立大学法人 東京大学 | 擬似運動療法のための医薬 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2008133141A1 (ja) * | 2007-04-24 | 2010-07-22 | 東洋紡績株式会社 | オスモチン組換えタンパク質およびその製造方法、並びにその利用 |
IN2013MU01939A (ja) * | 2013-06-03 | 2015-05-29 | Chitra Vasant Savangikar | |
US20170246245A1 (en) * | 2014-09-15 | 2017-08-31 | Industry-Academic Cooperation Foundation Gyeongsang National University | Novel pharmaceutical composition for treating alzheimer's disease |
CN107567284B (zh) | 2015-03-04 | 2020-09-29 | 庆尚大学校产学协力团 | 含有渗透蛋白肽作为有效成分的用于预防、改善或治疗神经疾病的组合物 |
EP3436075A4 (en) * | 2016-04-02 | 2020-01-01 | Chitra Vasant Savangikar | PLANT FRACTIONS WITH ANTI-PATHOGENESIS PROPERTIES |
WO2019186579A1 (en) * | 2018-03-25 | 2019-10-03 | Chitra Vasant Savangikar | Plant fractions having anti-pathogenesis properties |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05502168A (ja) * | 1990-06-07 | 1993-04-22 | シンヘンタ モーヘン ベースローテン フェンノートシャップ | 新規な抗菌調製物、該調製物の製造方法および菌類耐性の大きい植物の作製方法 |
AU2003242352A1 (en) * | 2002-12-29 | 2004-07-29 | Center For Advanced Science And Technology Incubation, Ltd. | Adiponectin receptor and gene coding for the same |
-
2005
- 2005-09-26 US US11/234,115 patent/US20060069024A1/en not_active Abandoned
- 2005-09-27 JP JP2007533697A patent/JP2008514626A/ja active Pending
- 2005-09-27 EP EP05813097A patent/EP1802323A2/en not_active Withdrawn
- 2005-09-27 WO PCT/US2005/034368 patent/WO2006036871A2/en active Application Filing
-
2007
- 2007-12-26 US US12/005,333 patent/US7803854B2/en not_active Expired - Fee Related
- 2007-12-26 US US12/005,236 patent/US7803556B2/en not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011115106A1 (ja) * | 2010-03-16 | 2011-09-22 | 国立大学法人 東京大学 | 擬似運動療法のための医薬 |
JPWO2011115106A1 (ja) * | 2010-03-16 | 2013-06-27 | 国立大学法人 東京大学 | 擬似運動療法のための医薬 |
Also Published As
Publication number | Publication date |
---|---|
WO2006036871A3 (en) | 2006-07-20 |
US20090018065A1 (en) | 2009-01-15 |
WO2006036871A2 (en) | 2006-04-06 |
US7803854B2 (en) | 2010-09-28 |
US20080177028A1 (en) | 2008-07-24 |
US20060069024A1 (en) | 2006-03-30 |
US7803556B2 (en) | 2010-09-28 |
EP1802323A2 (en) | 2007-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Narasimhan et al. | Osmotin is a homolog of mammalian adiponectin and controls apoptosis in yeast through a homolog of mammalian adiponectin receptor | |
US7803556B2 (en) | Plant PR-5 proteins as mammalian therapeutic agents | |
O'Neill et al. | Regulation of PHO4 nuclear localization by the PHO80-PHO85 cyclin-CDK complex | |
Cosentino et al. | Eap1p, a novel eukaryotic translation initiation factor 4E-associated protein in Saccharomyces cerevisiae | |
Van Heusden et al. | The 14‐3‐3 proteins encoded by the BMH1 and BMH2 genes are essential in the yeast Saccharomyces cerevisiae and can be replaced by a plant homologue | |
Esnault et al. | The yeast SSS1 gene is essential for secretory protein translocation and encodes a conserved protein of the endoplasmic reticulum. | |
Bartel et al. | The recognition component of the N‐end rule pathway. | |
Tamás et al. | Fps1p controls the accumulation and release of the compatible solute glycerol in yeast osmoregulation | |
Tedford et al. | Regulation of the mating pheromone and invasive growth responses in yeast by two MAP kinase substrates | |
Alconada et al. | The mitochondrial receptor complex: the small subunit Mom8b/Isp6 supports association of receptors with the general insertion pore and transfer of preproteins | |
US7081360B2 (en) | Expression of G protein-coupled receptors with altered ligand binding and/or coupling properties | |
Bahn et al. | Increased high‐affinity phosphodiesterase PDE2 gene expression in germ tubes counteracts CAP1‐dependent synthesis of cyclic AMP, limits hypha production and promotes virulence of Candida albicans | |
EP1167526B1 (en) | IgE-dependent histamine-releasing factor(HRF)receptor, HRF-binding peptides and nucleic acids encoding the same, and uses thereof | |
Sherman et al. | Multiple domains of fission yeast Cdc19p (MCM2) are required for its association with the core MCM complex | |
Van Dijck et al. | Nutrient sensing at the plasma membrane of fungal cells | |
US7361498B2 (en) | Yeast cells expressing modified G proteins and methods of use therefor | |
KR20240004152A (ko) | 엑소좀을 이용하는 covid-19 백신 또는 치료용 약제학적 조성물 | |
da Silva et al. | Insight into the α-amylase inhibitory activity of plant lipid transfer proteins | |
US6294363B1 (en) | Rapid method of proteasome purification using proteins having sequence homology to ubiquitin | |
Cohen et al. | Functional expression of rat GLUT 1 glucose transporter in Dictyostelium discoideum | |
US6355473B1 (en) | Yeast cells having mutations in stp22 and uses therefor | |
Narasimhan et al. | Osmotin is a Homolog of Human Adiponectin and Controls Apoptosis in Yeast Through a Homolog of Human Adiponectin Receptor | |
US6251605B1 (en) | Yeast cells having mutations in Cav1 and uses therefor | |
EP1626984A1 (en) | Spheron components useful in determining compounds capable of treating symptoms of alzheimer's disease | |
US20030108999A1 (en) | Cell having amplified signal transduction pathway responses and uses therefor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080926 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110607 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110905 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110912 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120124 |